Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pro-ocular 1% for Chronic Ocular GvHD
NCT03990051Phase 2Completed
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic ocular graft-versus-host disease (oGVHD) comparing Pro-ocular™ with Placebo (2 arms). Primary endpoints: Modified SANDE Questionnaire - Frequency at 2 years and Corneal Fluorescein Stain - Central at 2 years. Started Oct 2019; status: completed.
02
Drugs
progesterone
03
Conditions
chronic ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on NCT03990051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990051.